Mineralys Therapeutics Stock (NASDAQ: MLYS)

Mineralys Therapeutics (NASDAQ:MLYS) Stock, Unusual Options

Mineralys Therapeutics

Mineralys Therapeutics, Inc. - Common Stock

Overview

News

Earnings

Options

Analyst Ratings

Insider Trades

Short Interest

Stock Report

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Comments

Mineralys Therapeutics Unusual Options